The CooperCOO +3.13%84 Cyclically Adjusted PS Ratio is 4.09 as of Jul. 06, 2026, which is 39% below its 10-year median of 6.70. GuruFocus rates COO with a GF Score™ of 84/100 and a GF Value™ of $101.02 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 524 Medical Devices & Instruments companies, The Cooper ranks worse than 65.84% on this metric.
The historical rank and industry rank for The Cooper's Cyclically Adjusted PS Ratio or its related term are showing as below:
COO'
s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 3.28 Med: 6.7 Max: 9.78
Current: 4.09
During the past years, The Cooper's highest Cyclically Adjusted PS Ratio was 9.78. The lowest was 3.28. And the median was 6.70.
COO's Cyclically Adjusted PS Ratio is ranked worse than 65.84% of 524
companies
in the Medical Devices & Instruments industry
Industry Median: 2.295
vs COO: 4.09
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.
The Cooper's adjusted revenue per share data for the three months ended in Apr. 2026 was $5.546. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $18.16 for the trailing ten years ended in Apr. 2026.
Shiller PE for Stocks: The True Measure of Stock Valuation
The Cooper (NAS:COO) Cyclically Adjusted PS Ratio Explanation
Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.
The Cooper Cyclically Adjusted PS Ratio Related Terms
The Cooper Cyclically Adjusted PS Ratio Historical Data
* Premium members only.
The historical data trend for The Cooper's Cyclically Adjusted PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
COO vs SOLV, ALGN, BAX: Cyclically Adjusted PS Ratio Comparison
For the Medical Instruments & Supplies subindustry, The Cooper's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
The Cooper Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, The Cooper's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where The Cooper's Cyclically Adjusted PS Ratio falls into.
The Cooper Cyclically Adjusted PS Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.
The Cooper's Cyclically Adjusted PS Ratio for today is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PS Ratio of 4.09 mean?
The Cooper (COO) has a Cyclically Adjusted PS Ratio of 4.09 as of Jul. 06, 2026. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on The Cooper and its competitors. This is 39% below median its historical median of 6.70. Over the past decade, The Cooper's Cyclically Adjusted PS Ratio has ranged from 3.28 to 9.78. According to the industry distribution chart, The Cooper ranks #345 out of 524 companies in the Medical Devices & Instruments industry, placing it in the top 65.8%.
Is The Cooper's Cyclically Adjusted PS Ratio too high?
The Cooper's current Cyclically Adjusted PS Ratio of 4.09 is 39% below median its 10-year median of 6.70. Over the past 10 years, this metric has ranged from a low of 3.28 to a high of 9.78. The Medical Devices & Instruments industry median Cyclically Adjusted PS Ratio is 2.30. The Cooper's value of 4.09 is 78.2% above this industry median. Based on the distribution chart, The Cooper ranks #345 out of 524 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, The Cooper has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does The Cooper's Cyclically Adjusted PS Ratio compare to SOLV and ALGN?
According to the Medical Devices & Instruments industry distribution chart, The Cooper ranks #345 out of 524 companies for Cyclically Adjusted PS Ratio. This places The Cooper in the lower half of its industry. The industry median Cyclically Adjusted PS Ratio is 2.30. The Cooper's value of 4.09 is 78.2% above this benchmark. Historically, The Cooper's own Cyclically Adjusted PS Ratio has ranged from 3.28 to 9.78 over the past decade. While the company's 10-year median is 6.70 vs. the industry median of 2.30, The Cooper has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PS Ratio for a Medical Devices & Instruments company?
The median Cyclically Adjusted PS Ratio among Medical Devices & Instruments companies is 2.30, based on 524 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. The Cooper's current Cyclically Adjusted PS Ratio of 4.09 is 78.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PS Ratio mean?
A high Cyclically Adjusted PS Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on The Cooper and its competitors. For the Medical Devices & Instruments industry, the median Cyclically Adjusted PS Ratio is 2.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. The Cooper's current Cyclically Adjusted PS Ratio is 4.09, which is 39% below median its own 10-year median of 6.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is The Cooper stock overvalued right now?
Based on GuruFocus' analysis, The Cooper (COO) is currently considered Modestly Undervalued. The stock's GF Value™ is $101.02, compared to a current price of $74.20 — trading 26.5% below its estimated fair value. The current Cyclically Adjusted PS Ratio is 4.09, which is 39% below median its 10-year median of 6.70 and 78.2% above the Medical Devices & Instruments industry median of 2.30. The Cooper's overall GF Score™ is 84/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PS Ratio calculated?
Cyclically Adjusted PS Ratio is calculated from a company's financial statements. For The Cooper (COO), the current Cyclically Adjusted PS Ratio is 4.09 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is The Cooper (COO) Overvalued in 2026?
Based on GuruFocus' analysis, The Cooper stock appears to be undervalued.
The current stock price of $74.20 is trading 26.5% below its estimated GF Value™ of $101.02.
GuruFocus considers The Cooper to be Modestly Undervalued.
Key valuation signals for COO:
Cyclically Adjusted PS Ratio: 4.09 (39% below median its 10-year median of 6.70)
GF Value™: $101.02 vs. price of $74.20 (26.5% below fair value)
Industry Position: 78.2% above the Medical Devices & Instruments median (#345 of 524)
No single metric tells the full story. See the COO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CooperCompanies is one of the largest eyecare companies in the US. It operates in two segments: CooperVision and CooperSurgical. CooperVision is a pure-play contact lens business with a suite of spherical, multifocal, and toric contact lenses. The company also has one of the most comprehensive specialty lens portfolios in the world. With brands including Proclear, Biofinity, MyDay, and Clariti, Cooper controls roughly one fourth of the US contact lens market. CooperSurgical, founded in 1990, is made up of equipment related to reproductive care, fertility, and women's care. Cooper has the broadest medical device coverage of the entire IVF cycle. It also has Paragard, the only hormone-free IUD in the US, and controls 17% of the US IUD market.
84GF Score
Get the complete analysis for COO
Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
COO has been successfully added to your 
